Healthcare stocks are trailing the broader market by margins not seen since 2008, as tumbling pharma giants and a stampede toward tech and AI names have left the sector deeply out of interest.
The Healthcare Select Sector SPDR Fund (NYSE:XLV) now trades at just 0.2234 shares of the S&P 500 ETF Trust (NYSE:SPY), its weakest relative value in more than a decade. In 2015, that ratio was 0.35, making today’s level a 40% drop in comparative value.
In May 2025, healthcare lagged the S&P 500 by 11.2%, the worst single-month relative performance since records began. Versus the red-hot tech sector, the gap is even more extreme — at levels last seen in February 2000.
Have we been here before? Yes, and history suggests this kind of extreme undervaluation often triggers powerful reversals.
Chart: TradingView
After similar dislocations in May 2008 and October/November 2001, healthcare stocks sharply outpaced the broader market.
From November 2001 to September 2002, the sector outperformed the S&P 500 by 41%. From June 2008 to February 2009, it beat the market by a similar 40%.
When compared to tech stocks, the comeback is even more dramatic.
Between March 2000 and September 2002, healthcare outperformed the Invesco QQQ Trust (NASDAQ:QQQ) by a staggering 390% as the dot-com bubble burst.
These episodes followed the same pattern: investors often chased growth stocks until valuations became extreme.
Healthcare, seen as a comparatively safer sector, then spiked as capital rotated back to battered value and defensive names.
Big pharma and healthcare insurers are dragging the whole sector lower. UnitedHealth Group Inc. (NYSE:UNH) is down 40% year to date, its second-worst year since 1987.
Eli Lilly and Co. (NYSE:LLY) fell 18% in May, its steepest monthly drop since February 2009.
Meanwhile, Merck & Co. Inc. (NYSE:MRK) has logged nine straight months of declines — a feat unmatched since the company went public in 1970.
Wall Street analysts are optimistic that the sector might soon head towards a turnaround.
Of the 60 companies in the Healthcare Select Sector SPDR Fund, 59 have average 12-month analyst price targets above current market prices. The sector's weighted average upside stands at 17%.
For key players in the sector, Eli Lilly has a median analyst target that’s 22% above its current share price. UnitedHealth Group is expected to rise by 18%, while Merck & Co. is forecasted 27% higher the next 12 months.
More traditional valuation metrics also support the bullish case. The sector trades at a forward price-to-earnings ratio of 21, well below the 30 for the S&P 500 — highlighting just how steep the current discount is.
Read now:
Photo: Shutterstock